middle.news
Patrys Acquires Reliis to Fast-Track Injectable Delirium Treatment
9:46am on Wednesday 28th of January, 2026 AEDT
•
Healthcare
Read Story
Patrys Acquires Reliis to Fast-Track Injectable Delirium Treatment
9:46am on Wednesday 28th of January, 2026 AEDT
Key Points
Acquisition of Reliis includes 110 million shares and 70 million performance rights
Lead product AQS targets delirium with rapid onset injectable quetiapine
FDA 505(b)(2) reformulation pathway enables faster, lower-cost development
Market opportunity exceeds US$2 billion annually across ICU, palliative and aged care
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PATRYS (ASX:PAB)
OPEN ARTICLE